Pierre Fabre wins EC approval for Braftovi regimen in BRAFV600E‑mutant mCRC

23rd June 2026 Uncategorised 0

Breakwater phase 3 data show significant gains in progression‑free survival

More: Pierre Fabre wins EC approval for Braftovi regimen in BRAFV600E‑mutant mCRC
Source: News